Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Search research articles

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
[human Papillomavirus Type 18 - In Memoriam].

Home
Research Domains
Biomedical And Clinical Sciences
Oncology And Carcinogenesis
Predictive And Prognostic Markers
[human Papillomavirus Type 18 - In Memoriam].

Related Experiment Video

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

[Human papillomavirus type 18 - In memoriam].

Joakim Dillner¹

¹.

|August 6, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

High-risk Human Papillomavirus (HPV) types 16 and 18 cause significant cervical cancer. Expanding HPV vaccination to include more types and increasing participation is crucial for virus elimination and achieving herd immunity.

More Related Videos

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

Related Experiment Videos

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

Area of Science:

Oncology
Virology
Public Health

Background:

Human Papillomavirus (HPV) is a major cause of cervical cancer, with HPV 18 responsible for 19% of cases in Sweden, particularly adenocarcinomas.
High vaccination coverage is essential for eliminating oncogenic HPV types (e.g., HPV 16, 18) and medium-oncogenic types (e.g., HPV 31, 33, 45, 52, 58).

Purpose of the Study:

To assess the impact of HPV vaccination strategies on cervical cancer elimination.
To determine the required vaccination coverage for eliminating specific HPV types.

Main Methods:

Analysis of HPV vaccination coverage data in Sweden for women born 1994-1998.
Evaluation of the effectiveness of current and proposed HPV vaccination programs.

Main Results:

Catch-up vaccination against HPV 16 and 18 for women born 1994-1998 had only 55% participation, insufficient for virus elimination.
Achieving approximately 70% participation in vaccination against HPV types 16, 18, 31, 33, 45, 52, and 58 is projected to eliminate medium-oncogenic types and establish population immunity for HPV 16/18.
A national project offering free vaccines and screening since 2021 has shown a significant reduction in HPV 18 cases in highly vaccinated groups.

Conclusions:

Expanding HPV vaccination to include a broader range of oncogenic types and increasing participation are critical for cervical cancer prevention.
The ongoing national project shows promising early results for HPV elimination, indicating the potential for imminent extinction of HPV 18.